Utrecht, Netherlands

Gerard Pasterkamp

USPTO Granted Patents = 1 

 

 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gerard Pasterkamp: Innovator in Ischemia Reperfusion Injury Treatment

Introduction

Gerard Pasterkamp is a distinguished inventor based in Utrecht, Netherlands. He has made significant contributions to the field of medical innovations, particularly in the treatment of ischemia reperfusion injury. With a focus on novel therapeutic solutions, Pasterkamp holds one patent that addresses critical issues relating to tissue damage.

Latest Patents

Pasterkamp's notable patent is titled "Composition and method for treatment of reperfusion injury and tissue damage." This innovative work provides compounds and methods aimed at treating and preventing ischemia reperfusion injury. The invention particularly highlights compounds that serve to suppress the biological function or expression of Toll-like Receptor 2.

Career Highlights

Throughout his career, Gerard Pasterkamp has been associated with Opsona Therapeutics Limited, where he continues to advance his research and innovations. His work is integral to optimizing therapeutic approaches that can make a meaningful impact on patient outcomes in the medical field.

Collaborations

Collaborating with esteemed colleagues such as Mark Heffernan and Luke O'Neill, Pasterkamp has strengthened his endeavors and broadened the scope of his research. These collaborations highlight the interdisciplinary nature of his work and the importance of teamwork in innovating effective medical treatments.

Conclusion

Gerard Pasterkamp's contributions to the field of medical innovation are noteworthy, particularly his work on treatments for ischemia reperfusion injury. Through his patent and collaborative efforts, Pasterkamp is poised to make lasting impacts in healthcare, demonstrating the power of innovation in addressing significant medical challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…